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Abstract
DNA-sensing receptor Cyclic GMP–AMP Synthase (cGAS) and its downstream signal-
ing effector STimulator of INterferon Genes (STING) have gained significant interest 
in the field of tumor immunology, as a dysfunctional cGAS-STING pathway is associ-
ated with poor prognosis and worse response to immunotherapy. However, studies 
so far have not taken into account the polymorphic nature of the STING-encoding 
STING1 gene. We hypothesized that the presence of allelic variance in STING1 would 
cause variation between individuals as to their susceptibility to cancer development, 
cancer progression, and potential response to (immuno)therapy. To start to address 
this, we defined the genetic landscapes of STING1 in cervical scrapings and investi-
gated their corresponding clinical characteristics across a unique cohort of cervical 
cancer patients and compared them with independent control cohorts. Although we 
did not observe an enrichment of particular STING1 allelic variants in cervical cancer 
patients, we did find that the occurrence of homozygous variants HAQ/HAQ and 
R232H/R232H of STING1 were associated with both younger age of diagnosis and 
higher recurrence rate. These findings were accompanied by worse survival, despite 
comparable mRNA and protein levels of STING and numbers of infiltrated CD8+ T 
cells. Our findings suggest that patients with HAQ/HAQ and R232H/R232H geno-
types may have a dysfunctional cGAS-STING pathway that fails to promote efficient 
anticancer immunity. Interestingly, the occurrence of these genotypes coincided with 
homozygous presence of the V48V variant, which was found to be individually asso-
ciated with worse outcome. Therefore, we propose V48V to be further evaluated as 
a novel prognostic marker for cervical cancer.
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1  | INTRODUC TION
Cervical cancer is the fourth most common type of cancer in women 
worldwide and the leading cause of cancer deaths in over 50 coun-
tries.1 A persistent human papillomavirus (HPV) infection under-
lies the development of cervical cancer.2 In recent years, several 
genomewide association studies have led to the discovery of mul-
tiple genes influencing the susceptibility to cervical cancer.3 Allelic 
variants of these genes together may explain up to 24% of the vari-
ance in the risk for developing cervical cancer.4 One of the genes is 
STING1 (also known as TMEM173 and MITA), encoding STimulator of 
INterferon Genes (STING), which is a downstream signaling effec-
tor of the DNA-sensing receptor Cyclic GMP–AMP Synthase (cGAS). 
During infections, cGAS detects DNA from pathogens in the cytosol 
of the cell and subsequently elicits STING activation and ultimately 
induction of interferon type I (IFN-I) signaling, thereby provoking in-
nate and, subsequently, adaptive immunity.5
In the context of cancer, the cGAS-STING pathway can identify 
chromosomal instability in cancerous cells by detecting cytoplasmic 
DNA6-8 or identify infection with potentially carcinogenic viruses 
by detecting viral DNA, such as DNA from HPV.9 In addition, it is 
reported to improve the efficacy of (DNA damage–inducing) ra-
diotherapy.10,11 Several studies have shown that dysfunction of 
the cGAS-STING pathway, caused for instance by deficient STING 
translocation to the Golgi and decreased expression levels of cGAS 
and STING, leads to poor IFN-I production.10,12-16 In multiple can-
cer types such as breast, gastric, and hepatocellular carcinoma, lev-
els of STING were found to be decreased compared with healthy 
tissue.14-16 In another study regarding DNA damage, loss of STING 
hampered tumor regression upon application of multiple therapeu-
tic strategies such as immune checkpoint blockade.8 As loss and 
decreased levels of STING are associated with poor prognosis,15-17 
the potential therapeutic benefit of inducing STING is currently 
under investigation.18 However, the existence of allelic variants 
of the STING gene may complicate the efficacy of this treatment 
modality because some variants cause an inherent defect in STING 
functionality.19,20 A total of 76 biallelic variants are observed in the 
STING-encoding STING1 gene. Of these, 26 are located in the cod-
ing sequence. Moreover, six represent synonymous substitutions, 
among which is rs7447927 (V48V, c.144C > G).21 The most com-
mon variants in STING1 are the nonsynonymous rs1131769 (R232H, 
c.695G > A), rs11554776 (R71H, c.212G > A), rs78233829 (G230A, 
c.689G > C), and rs7380824 (R293Q, c.878G > A).21,22 In combina-
tion, the latter three are termed the HAQ genotype, which occurs in 
20.4% of the human population.21 The R232H, G230A, and R293Q 
substitutions are located in the CDN-binding region of the gene and 
cause defective response of STING.23 For instance, a recent study 
reported on the effect of the homozygous HAQ variant of STING 
in individuals infected with human immunodeficiency virus (HIV), 
stating that it contributes to reduced levels of IFN production and a 
reduced immune response.24
In the context of HPV infection, we hypothesized that allelic 
variants of STING1 may increase the susceptibility of patients to 
persistent infection and thereby risk of cervical cancer development. 
Furthermore, we hypothesized that the occurrence of particular 
variants may affect immunity against established cervical cancer. To 
investigate this, we comprehensively defined the variance in STING 
by genotyping STING1 and assessing CD8+T cell infiltration across a 
large cohort of cervical cancer patients.
2  | MATERIAL S AND METHODS
2.1 | Patient cohort
All patients visiting the outpatient clinic of the University Medical 
Center Groningen (UMCG, the Netherlands) for diagnostics or treat-
ment of cervical neoplasia or nonmalignant reasons (such as uter-
ovaginal prolapse or uterine myomas) were asked to participate. 
After informed consent, frozen tissue samples and cervical epithe-
lial scrapings were collected. The cervical scrapings cells were sus-
pended in 250 µL of 4M guanidium isothiocyanate (GT) and frozen 
at −80°C. Frozen tissue was embedded with Tissue-Tek® OCT™ 
Compound (Sakura Finetek Europe BV) and stored at −80°C. RNA 
was isolated using Ambion TRIzol Reagent (Invitrogen) or by chlo-
roform/isopropanol precipitation. cDNA was synthesized using 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV 
RT). Data of healthy controls, patient and tumor characteristics, 
and clinical follow-up data were collected retrospectively in an an-
onymized database (see also document S1 for detailed experimen-
tal procedures). Ethical approval for the study was provided by the 
medical ethics review committee (METc) of the UMCG (study num-
ber 201800288).
2.2 | Analysis of STING1 expression and 
allelic variance
STING1 cDNA was isolated through PCR amplification, followed by gel 
extraction and Sanger sequencing. The reference sequences of the 
STING1 mRNA transcript were obtained online from National Center 
for Biotechnology Information Gene.25 To determine prevalence of al-
lelic variants, data from the NCBI 1000 Genomes phase 3 browser26 
were analyzed, containing data from 2504 whole genomes (5008 gen-
otypes), of which 503 (1006 genotypes) were from European donors 
(107 Spanish, 107 Italian, 99 Finnish, 91 British, and 99 Utah residents 
with a European background). This population is further referred to as 
European reference cohort and used as additional reference for the 
allele and genotype frequencies in the current study population. The 
following six STING1 single-nucleotide substitutions were included for 
analysis: V48V, R71H, G230A, R232H, R293Q, and A313T. Somatic 
substitutions such as R284M and R284G were not taken into account, 
as it was formerly reported that the mutation rate in STING1 is only 
0.11%.23 Combinations of single-nucleotide substitutions were an-
notated either as HAQ genotype (V48V, R71H, G230A, and R293Q), 
R232H genotype (V48V and R232H), or AQ genotype (V48V, G230A, 
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and R293Q); A313T was not observed in the patient cohort. Expression 
analysis of STING1 was performed by qRT-PCR (see also document S1 
for detailed experimental procedures).
2.3 | Immunohistochemistry
Whole tumor tissue sections of 89 and 99 included cervical cancer pa-
tients were stained for STING and CD8, respectively. Formalin-fixed, 
paraffin-embedded (FFPE) slides (obtained from the UMCG Pathology 
Biobank) were deparaffinized and rehydrated in graded ethanol. 
Antigen retrieval was instigated by 15 minutes of microwave in pre-
heated 10 mmol/L citrate buffer (pH 6.0). Endogenous peroxidase was 
blocked by incubating the slides in 0.45% hydrogen peroxide solution 
for 30 minutes. To stain for STING and CD8, the slides were incubated 
overnight at 4°C with, respectively, monoclonal rabbit anti-human 
TMEM173 antibody (EPR13130, ab181125, Abcam) and monoclonal 
mouse anti-human CD8 antibody (clone C8/144B, Agilent [Dako], 
M710301), diluted 50X in PBS containing 1% BSA and 1% human AB 
serum. Next, the slides were incubated for 30 minutes with Envision+/
HRP anti-rabbit or anti-mouse antibody (Agilent [Dako]). Signal was 
visualized with 3,3'-diaminobenzidine (DAB) solution containing hy-
drogen peroxide, and the slides were counterstained with hematox-
ylin. In between incubations, the slides were washed with PBS. The 
sections were dehydrated and embedded in Eukitt quick-hardening 
mounting medium (Sigma Aldrich), and the slides were scanned using 
a Hamamatsu digital slide scanner (Hamamatsu Photonics). The num-
bers of STING + and CD8+ cells in each slide were quantified auto-
matically using QuPath v0.1.2 image analysis software27 after manual 
selection of tumor epithelium sections.
2.4 | Statistics
Genotype counts were compared between patients and controls 
and the effects of allelic variants on clinical characteristics were 
assessed using chi-square testing. The effect of allelic variants on 
the risk of developing cervical cancer was determined by compar-
ing allele frequencies between patients and controls and patients 
and the European reference cohort using odds ratios and confi-
dence intervals, not adjusted for any external variable. Differences 
between age of diagnosis, STING1 expression levels (delta Ct val-
ues), STING levels, and CD8 infiltration (number of positive cells per 
mm2) between the study groups were analyzed using Kruskal-Wallis 
testing with post-Dunn tests. Survival was analyzed with Kaplan-
Meier curves (log-rank) and univariate and multivariate Cox regres-
sion tests. Variables with a P-value < .05 in the univariate analyses 
were included in the multivariate analyses (Forward Stepwise LR). 
Significant associations were defined by a P-value lower than 0.05. 
Statistics were performed using SPSS software version 23.0 (IBM 
SPSS Statistics) or GraphPad Prism 7.02 (GraphPad Software).
3  | RESULTS
3.1 | Allelic variants in STING1 are not enriched in 
cervical cancer
We speculated that allelic variants in the cGAS-STING pathway 
could predispose to the development of cervical cancer due to the 
failure of the innate immune system to clear HPV-infected cells. To 
investigate this hypothesis, we genotyped STING1 (encoding STING) 
using cervical scrapings of 150 cervical cancer patients and 20 age-
matched healthy controls and compared the results with 503 indi-
viduals in the European reference cohort.26 In the patient cohort, we 
found the following genotypes: WT/WT (58.0%), WT/HAQ (18.0%), 
WT/R232H (14.7%), WT/AQ (0.7%), HAQ/HAQ (3.3%), HAQ/R232H 
(2.0%), R232H/R232H (2.7%), and R232H/AQ (0.7%) (Table 1). Only 
four of these eight genotypes were found in the healthy controls: 
WT/WT (55.0%), WT/HAQ (15.0%), WT/R232H (20.0%), and HAQ/
R232H (5.0%). In addition, one healthy control had the genotype 







WT/WT 87 (58.0) 11 (55.0) 258 (51.3)
WT/HAQ 27 (18.0) 3 (15.0) 97 (19.3)
WT/R232H 22 (14.7) 4 (20.0) 88 (17.5)
WT/AQ 1 (0.7) - 3 (0.6)
WT/A313T - 1 (5.0) 4 (0.8)
WT/G230A - - 1 (0.2)
HAQ/HAQ 5 (3.3) - 14 (2.8)
HAQ/R232H 3 (2.0) 1 (5.0) 22 (4.4)
R232H/R232H 4 (2.7) - 14 (2.8)
R232H/AQ 1 (0.7) - -
HAQ/AQ - - 1 (0.2)
AQ/AQ - - 1 (0.2)
TA B L E  1   Distribution of STING1 
genotypes across patient and control 
cohorts
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Notably, the well-described HAQ variant was not found as homozy-
gous genotype in the healthy control cohort. The genotypes WT/
G230A, HAQ/AQ, and AQ/AQ, which have been reported for the 
European reference cohort,26 were not found in both the patient 
and healthy control cohorts. However, the overall distribution of 
STING1 genotypes within the patient population was comparable 
to the distribution of the healthy controls and European reference 
cohort. About half (58.0%) of the patient samples were character-
ized by two wild-type STING alleles (WT/WT), lacking each of the 
examined variants, whereas the minority of patients contained a sin-
gle allele (WT/VAR, 33.4%) or two variant alleles (VAR/VAR, 8.7%), 
containing at least one of the examined substitutions on one allele 
or both alleles, respectively. This genotype distribution was compa-
rable to the distribution found within the group of healthy controls 
(55.0%, 40.0%, and 5.0%, respectively) and within the European 
reference population (51.3%, 38.4%, and 10.4%, respectively).26 In 
addition, the prevalence of individual STING1 alleles in the cohort 
of cervical cancer patients was similar as well, with no allele show-
ing an (significant) enrichment within the patient cohort (Table S1). 
The synonymous substitution rs7447927 (V48V) had a slightly, but 
not significantly, higher abundance in the European reference cohort 
than in the (Dutch) patient and healthy control cohorts (patient vs. 
European reference cohort P = .074). Altogether, we suggest that 
allelic variants of STING1 are not a crucial factor for persistent infec-
tion of HPV and that these variants do not predispose to the devel-
opment of cervical cancer.
3.2 | Homozygous variants of STING1 are 
associated with cervical adenocarcinomas
We next assessed whether the allelic variants could affect disease 
progression by analyzing the clinical characteristics of the patients 
(Table 2, Table S2). As to tumor typing, 59.8% of the patients with 
WT/WT genotype had squamous cell carcinomas and 35.6% had ad-
enocarcinomas (Figure S1A). In contrast, we found that only 23.1% 
of patients with VAR/VAR genotype had squamous cell carcinomas, 
whereas nearly 70% of these patients presented with adenocarcino-
mas. Patients with WT/VAR genotypes showed histological distri-
bution comparable to patients with a WT/WT genotype. Although 
allelic variants appear to skew towards adenocarcinoma subtype, 
the overall difference in histological distribution between the three 
groups WT/WT, WT/VAR, and VAR/VAR did not reach significance 
(P = .138).
We also noticed that the tumor diameters of patients with WT/
WT and WT/VAR genotypes tended to be larger than those of pa-
tients with a VAR/VAR genotype (Figure S1B). In addition, nearly 
70% of patients with VAR/VAR genotypes were diagnosed with 
early-stage cervical cancer (up to FIGO stage IB1) with a highest 
FIGO classification of IIB (Figure S1C). In contrast, only half of the 
patients with at least one wild-type allele were diagnosed with 
early-stage cervical cancer, and the rest was diagnosed with FIGO 
stage IB2 or higher. Here, the highest FIGO stage found was IVB. 
TA B L E  2   Clinical characteristics of patients divided in STING1 








Patients 87 (58.0) 50 (33.3) 13 (8.7)
Age at diagnosis (in years)
Median 51.3 48.2 40.1
Range 22.9-83.9 27.3-87.9 25.2-58.3
HPV status
Negative 3 4 0
Positive 34 9 2
Unknown 50 37 11
FIGO stage
IA 1 (1.1) 1 (2.0) 0 (0.0)
IB1 39 (44.8) 26 (52.0) 9 (69.2)
IB2 10 (11.5) 3 (6.0) 1 (7.7)
IIA 13 (14.9) 6 (12.0) 1 (7.7)
IIB 15 (17.2) 10 (20.0) 2 (15.4)
IIIA 1 (1.1) 0 (0.0) 0 (0.0)
IIIB 6 (6.9) 2 (4.0) 0 (0.0)
IVA 1 (1.1) 1 (2.0) 0 (0.0)




52 (59.8) 28 (56.0) 3 (23.1)
Adenocarcinoma 31 (35.6) 21 (42.0) 9 (69.2)
Other 4 (4.6) 1 (2.0) 1 (7.7)
Grade of differentiation
Good/moderate 40 (46.0) 25 (50.0) 7 (53.8)
Poor/undifferentiated 29 (33.3) 16 (32.0) 5 (38.5)
Unknown 18 (20.7) 9 (18.0) 1 (7.7)
Lymphangioinvasion
No 60 (69.0) 30 (60.0) 8 (61.5)
Yes 26 (29.9) 20 (40.0) 5 (38.5)
Unknown 1 (1.1) 0 (0.0) 0 (0.0)
Tumor diameter (cm)
0-4 42 (48.3) 21 (42.0) 9 (69.2)
≥4 27 (31.0) 17 (34.0) 2 (15.4)
Unknown 18 (20.7) 12 (24.0) 2 (15.4)
Primary treatment
Wertheim-Meigs 46 (52.9) 29 (58.0) 9 (69.2)
Radio-chemotherapy 32 (36.8) 14 (28.0) 2 (15.4)
Other 9 (10.3) 7 (14.0) 2 (15.4)
Follow-up (in years)





     |  5LUBBERS Et aL.
Patients with VAR/VAR genotypes tend to receive surgery more 
often than radiotherapy as their primary treatment (Figure S1D), 
which may be explained by their smaller tumor sizes and lower 
FIGO stages.
However, altogether, our analyses showed no significant differ-
ence between any of the discussed clinical factors.
3.3 | Homozygous variants of STING1 are 
prognostic factors in cervical cancer
Previous reports show that the 5-year survival of cervical cancer 
patients with metastasis is 16.5% compared with 91.5% without 
metastasis.28 In addition, in cancer models of chromosomal insta-
bility, metastasis was promoted in a STING-dependent manner.7 
Therefore, we assessed whether particular allelic variants of STING1 
were associated with metastasis. As expected, the occurrence of 
metastasis was significantly associated with poor outcome (Table 3, 
univariate cox regression, P < .001). However, we observed that the 
proportion of patients that presented with distant and lymph node 
metastasis was comparable for each of the WT/WT, WT/VAR, and 
VAR/VAR groups (Figures S1E and F, respectively), indicating that 
the occurrence of metastasis is independent of the different STING1 
variants. Although distant metastasis was significantly associated 
with a poor prognosis in the group of patients with at least one wild-
type allele (Kaplan-Meier, P < .001, not shown), we observed that 
occurrence of metastasis did not affect the outcome of patients with 
VAR/VAR genotypes of STING (Kaplan-Meier, P = .382, not shown). 
These patients have a poor prognosis regardless of having metasta-
sis or not, indicating that another factor causes the poor outcome of 
these patients.
To follow up on these findings, we assessed the effect of STING1 
variants on the disease-specific survival (DSS). Interestingly, the 
DSS of patients with HAQ/HAQ, R232H/R232H, and R232H/AQ 
genotypes was significantly worse than with WT/WT genotype 
(P = .049, P = .022, and P = .001, respectively, not shown). As 
the individual genotype groups were rather small, we next com-
pared the DSS between grouped WT/WT, WT/VAR, and VAR/
VAR genotypes and observed a significant difference in outcome, 
with patients with homozygous allelic variants of STING1 having a 
worse DSS than patients with wild-type or heterozygous variants 
(Figure 1A, P = .019). Although the DSS was slightly worse for the 
WT/VAR patients than for the WT/WT patients, this difference 
was not statistically significant (P = .114). Next, we hypothesized 
that the presence of at least one wild-type allele may result in 
functional STING and therefore grouped the patients with at least 
one wild-type allele for additional analysis of DSS. We show that 
having at least one wild-type allele significantly improves overall 
survival and DSS (Figure 1B, P = .007). Importantly, multivariate 
analysis of STING1 genotype groups and clinicopathological fac-
tors revealed an independent association of STING1 status with 
DSS (Table 3). Analysis of STING1 expression levels by qRT-PCR 
showed that the prognostic value was also independent of STING1 
mRNA levels, as these were statistically comparable for WT/
WT, WT/VAR, and VAR/VAR genotypes (Figure S2A, P = .207). 
Moreover, there was no significant difference in DSS (Figure S2B, 
P = .617) or in recurrence-free survival (Figure S2C, P = .226) 
based on above- and below-median STING1 mRNA levels. Similar 
results were found when immunohistochemically assessing STING 
protein levels in paraffin-embedded tumor tissue (Figure S3). We 
hypothesized that STING variants may affect responsiveness to 
therapy. Indeed, the DSS was worse for patients with homozygous 
STING variants, independently of the primary treatment being 
surgery or radiochemotherapy (RCT) (Figure 1F-1I). These data 
demonstrate that homozygous mutated variants of STING1 have 
independent prognostic value for patients with cervical cancer 
that cannot be explained by the levels of both STING mRNA and 
protein.
3.4 | Homozygous mutated variants of STING1 
appear to be associated with early onset of 
cervical cancer
To understand the worse survival of VAR/VAR STING patients, we 
further investigated differences in the clinical data of the patients. 
We noticed that the age of diagnosis significantly differed between 
the three genotype groups (Figure 1C, P = .0395). Specifically, the 
age of diagnosis was significantly lower for patients with VAR/VAR 
genotypes of STING1 than for patients with WT/WT (P = .0331). 
The median ages of diagnosis were 40.1 vs 51.3 and 48.2 years, 
respectively (Table 2). Especially the HAQ/HAQ (39.6 years) and 
R232H/R232H (36.9 years) genotypes contributed to this lower 
median age. When we subsequently compared the effect of the 
age at the time of diagnosis on the outcome, we observed that the 
DSS within the entire cohort of 150 patients was not significantly 
different between younger and older age of diagnosis (Figure S4, 
based on the median age of the entire cohort of 50.05, P = .224). 
This was also not the case when first stratifying the cohorts for 
adenocarcinoma vs squamous cell carcinoma (P = .146 vs P = .822, 
not shown). Thus, early onset of disease in itself is not a predictor 
of poor prognosis. Therefore, we suggest an independent negative 









No evidence of 
disease
63 (72.4) 36 (72.0) 6 (46.2)
Evidence of disease 1 (1.1) 1 (2.0) 0 (0.0)
Death of disease 17 (19.5) 13 (26.0) 7 (53.8)
Death of other disease 6 (6.9) 0 (0.0) 0 (0.0)
Abbreviation: HPV, human papillomavirus.
TA B L E  2   (Continued)
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TA B L E  3   Uni- and multivariate Cox regression survival analyses based on clinical and STING1 parameters
Univariate Multivariatea  Multivariateb 
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Age of diagnosis 
(cont)
0.977 0.954 1002 .070
Age (in years)
<50.04 median ref ref ref ref
>50.04 median 0.657 0.333 1.298 .227
Grade
Good ref ref ref ref
Average 0.980 0.358 2.685 .969
Bad/not 1.204 0.466 3.109 .701
Unknown 1.341 0.456 3.944 .594
FIGO stage
I ref ref ref ref
II 3.187 1.445 7.031 .004
III 6.959 2.374 20.401 <.001
IV 14.684 4.493 47.988 <.001
Typing
Squamous ref ref ref ref
Adeno 1.148 0.583 2.260 .690
Other 0.872 0.116 6.542 .894
Distant metastasis
No ref ref ref ref ref ref ref ref ref ref ref ref
Yes 14.952 7.160 31.225 <.001 14.458 6.327 33.041 <.001 14.970 6.410 34.963 <.001
Lymph node metastasis
No ref ref ref ref
Yes 8.637 3.762 19.830 <.001
Tumor diameter (cm)
0-4 ref ref ref ref
≥4 1.655 0.808 3.389 .168
Unknown 0.771 0.297 2.002 .594
Primary treatment
WM ref ref ref ref ref ref ref ref ref ref ref ref
RCT 3.753 1.618 8.705 .002 3.005 1.226 7.368 .016 2.860 1.176 6.956 .020
Other 10.413 4.143 26.169 <.001 12.163 4.317 34.269 <.001 11.559 4.152 32.175 <.001
STING1 genotype
WT/WT ref ref ref ref ref ref ref ref
WT/VAR 1.399 0.672 2.912 .369 2.169 0.999 4.708 .050
VAR/VAR 3.393 1.385 8.310 .008 3.516 1.315 9.397 .012
V48V/V48V
WT/WT ref ref ref ref ref ref ref ref
WT/VAR 1.271 0.600 2.689 .531 2.251 1.007 5.032 .048
VAR/VAR 3.564 1.512 8.400 .004 2.930 1.146 7.497 .025
CD8 infiltrate 
(cont)
1.000 0.999 1.000 .458
(Continues)
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3.5 | Homozygous variants of STING1 are 
associated with higher frequency of recurrences
In addition to being diagnosed at an earlier age, patients with VAR/
VAR variants notably suffered from recurrent disease significantly 
more often than patients with the WT/WT variant (Figure 1D, 
P = .018). To confirm whether the occurrence of recurrent disease 
explains the worse outcome of patients with VAR/VAR STING1, we 
performed additional Kaplan-Meier analyses in which we excluded ei-
ther all patients with recurrences or only the patients with VAR/VAR 
genotypes with recurrences. In both cases, there was no difference in 
survival between the groups (P = .942 and P = .642, respectively, not 
shown). In accordance, the recurrence-free survival was significantly 
better for the WT/WT group of patients (Figure 1E, P = .013) and, 
although insignificantly, for the WT/VAR group (P = .061), compared 
with the VAR/VAR group of patients. In total, 27 out of 150 patients 
suffered from a recurrence. From the 21 patients within this group 
with at least one WT allele, six (28.6%) survived the recurrent disease, 
whereas the six VAR/VAR patients that recurred all succumbed to the 
disease (not shown). Altogether, these findings show that although 
the initial clinical characteristics such as tumor diameter and FIGO 
stage of patients with VAR/VAR genotypes of STING appear slightly 
beneficial over patients with WT/WT and WT/VAR, having at least 
one wild-type allele may protect against (aggressive) recurrent dis-
ease and therefore improve outcome.
3.6 | The prognostic value of mutated STING1 
variants is independent of CD8+ T cell infiltration
High levels of STING protein expression were previously associ-
ated with high CD8+ T cell infiltration.17 In line with this, knock-
out of STING led to decreased infiltration of CD8+T cells in animal 
models.8 Although we observed no differences in STING expres-
sion between the genotypes, we hypothesized that the patients 
with VAR/VAR genotypes of STING1 might have lower CD8+T cell 
infiltration, possibly explaining the poor survival of these patients. 
To investigate this, we performed immunohistochemistry for 
CD8+T cells using paraffin-embedded tumor tissue of 99 cervical 
cancer patients from our cohort. Quantification of CD8+ T cells 
across the FFPE slides was performed using machine-based quan-
tification (Figure 2A). We found that CD8+ T cell infiltration did 
not differ between the three STING1 groups (Figure 2B, P = .687). 
Patient outcome in this cohort also did not reach statistical signifi-
cance for outcome based on low and high CD8+ T cell infiltration 
(Figure 2C and Table 3, P = .699). Lastly, there was no association 
between CD8+ T cell infiltration and STING1 expression (P = .295, 
not shown). Thus, homozygous variants of STING are prognostic 
factors in cervical cancer, independently of both STING1 expres-
sion and CD8+ T cell infiltration.
3.7 | The homozygous V48V variant of STING1 
represents a surrogate genetic marker for STING1 
variations associated with poor outcome in 
cervical cancer
When assessing the effect of having two wild-type alleles, one wild-
type allele, or no wild-type allele of each individual nucleotide sub-
stitution on survival, we found that most individual substitutions 
did not significantly affect DSS (not shown). Only the 14 patients 
with homozygous V48V presented with significantly worse outcome 
than patients with homozygous or heterozygous wild-type V48V 
(Figure 3A, P = .008). In addition, we observed that half of these 
patients suffered from recurrent disease, in contrast to patients with 
WT/WT and WT/VAR genotypes (14.0% and 16.0%, respectively) 
(Figure 3B, P = .005). In accordance, the recurrence-free survival 
was significantly worse for patients with homozygous mutated V48V 
when comparing the patients only based on this single-nucleotide 
substitution (Figure 3C, P = .005). Interestingly, V48V represents a 
synonymous substitution and therefore likely has no clinical implica-
tions in itself. Moreover, we described earlier that V48V variant is 
not enriched in the patient cohort. However, homozygous presence 
of V48V almost completely corresponded to the patients with VAR/
VAR genotypes of STING, with 13 patients having R232H/R232H, 
HAQ/HAQ, HAQ/R232H, or R232H/AQ (VAR/VAR) genotypes and 
only one of the 14 patients with homozygous V48V having a WT/AQ 
(WT/VAR) genotype of STING1. Altogether, our findings therefore 
indicate that homozygous V48V in STING1 may potentially be used 
Univariate Multivariatea  Multivariateb 
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
CD8 infiltratec 
Low ref ref ref ref
High 0.846 0.363 1.972 .699
Note: Disease-specific survival, Cox regression - Enter for univariate and Forward Stepwise (LR) for multivariate, n = 150.
Abbreviations: CI: Confidence Interval; FIGO: International Federation of Gynecology and Obstetrics; HR: Hazard Ratio; RCT: Radiochemotherapy.
aWhen STING1 genotype entered as variable, V48V/V48V not included. 
bWhen V48V/V48V entered as variable, STING1 genotype not included. 
cBased on below- or above-median CD8 count of 392 125 per mm2. 
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as a surrogate marker for a poor STING1 genotype–related outcome 
in cervical cancer.
4  | DISCUSSION
In this study, we genotyped the STING-encoding STING1 gene across a 
unique cohort of 150 cervical cancer patients and examined a panel of 
clinical characteristics. Notably, we found that homozygous variants 
of STING1 were significantly associated with worse survival outcome. 
This association was found to be independent of CD8+ T cell infiltra-
tion and STING1 expression. Thus, specific allelic variants of STING1 
may affect the development and progression of cervical cancer.
STING-encoding STING1 is one of the genes described to influ-
ence the susceptibility of an individual to cervical cancer.3 We gen-
otyped regions in the STING-encoding STING1 that can contain key 
single-nucleotide substitutions using cervical scrapings of 150 cervi-
cal cancer patients to investigate whether particular allelic variants in 
STING1 are enriched in cervical cancer patients and have a prognostic 
value. In accordance with the previous conclusion of Xiao et al that no 
variant of STING1 is associated with the risk of cervical precancerous 
lesions,29 we found no allelic variant of STING1 to be enriched in our 
cervical cancer patient cohort compared with healthy controls and a 
European reference population. This suggests that these allelic vari-
ants are not a crucial factor for persistent infection with HPV and that 
they do not predispose to the development of cervical cancer.
F I G U R E  1   Cervical cancer patients were analyzed regarding disease-specific survival (A, B), based on three groups (A): WT/WT (blue), 
WT/VAR (green), and VAR/VA (orange) or on two groups (B): WT/WT and WT/VAR combined (blue) and VAR/VAR (orange). C, Age at the 
time of diagnosis (in years) for the three described groups. Each orange dot represents one patient. Statistical analysis was performed by 
one-way ANOVA with post-hoc Kruskal-Wallis test. D, Distribution of recurrences (%) among the three described groups: Yes (recurrence, 
light blue) or No (no recurrence, orange). Statistical analysis was performed by Pearson’s chi-square testing. E, Recurrence-free survival (one-
minus plot) for WT/WT (blue), WT/VAR (green), and VAR/VAR (orange). F-I, Disease-specific survival distinguishing cervical cancer patients 
by primary treatment being surgery (F, G,) or RCT (H, I) and by distinguishing three groups (F, H): WT/WT (blue), WT/VAR (green), and VAR/
VA (orange) or two groups (G, I): WT/WT and WT/VAR combined (blue) and VAR/VAR (orange). For all survival curves, statistical analyses 
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Typically, the predominant histological subtype of cervical can-
cer is squamous cell carcinoma (70%-80% of cases), followed by 
adenocarcinoma (10%).2 Interestingly, we found that the nearly 
70% of patients in our cohort with VAR/VAR STING1 genotypes 
presented with adenocarcinomas. Moreover, we noticed that the 
tumor diameters of patients with WT/WT and WT/VAR genotypes 
often were larger, and the FIGO stages at diagnoses were often 
higher than those of patients with VAR/VAR genotypes, although 
these differences did not reach statistical significance. In addition, 
we observed that patients with VAR/VAR genotypes of STING1 
were diagnosed with cervical cancer at a significantly earlier age. 
The median age at diagnosis of cervical cancer is 48 years.30 In 
accordance, we found that the median ages of WT/WT and WT/
VAR patients were 51.3 and 48.2, respectively. In contrast, the me-
dian age of diagnosis for patients with homozygous variants was 
40.1 years. About half of the patients that were diagnosed at an 
age below the median of the entire cohort presented with ade-
nocarcinomas. These findings are in accordance with previous re-
ports that patients with adenocarcinomas are generally diagnosed 
at an earlier stage and at a younger age.31 Together, our findings 
may indicate again a link between homozygous variants of STING1¸ 
histology, and age of diagnosis.
Women with locally advanced cervical cancer have a higher rate 
of local and distant recurrences and worse survival than women that 
F I G U R E  2   Immunohistochemical staining of CD8 on formalin-fixed, paraffin-embedded (FFPE) slides of tumors obtained from the 
studied cervical cancer patient cohort. A, Microscopic image (400X magnification) of CD8 staining (left) and representation of the 
computerized quantification of membrane 3,3'-diaminobenzidine (DAB)-positive cells (red) and DAB-negative cells (blue) in QuPath image 
analysis software (right). B, Quantified numbers of DAB/CD8-positive cells per mm2 tumor tissue for the three groups: WT/WT, WT/VAR, 
and VAR/VAR. C, Disease-specific survival dividing patients into two groups: below (orange) and above (green) the median number of CD8 























































F I G U R E  3   Analysis of the single synonymous substitution rs7447927 V48V. A, Disease-specific survival dividing patients into three 
groups: WT/WT (blue), WT/VAR (orange), and VAR/VAR (green) (P = .008). B, Distribution of recurrences (%) among the three described 
V48V groups: Yes (recurrence, light blue) or No (no recurrence, orange). Statistical analysis was performed by Pearson’s chi-square testing. 
C, Recurrence-free survival (one-minus plot) based on the three described V48V groups. Statistical analyses for survival curves were 
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are diagnosed with early-stage disease.32,33 Interestingly, despite their 
tendency toward having early-stage disease, patients with VAR/VAR 
genotypes of STING had significantly worse disease-specific and recur-
rence-free survival than patients with WT/WT and WT/VAR genotypes. 
Hence, having at least one wild-type allele may partially protect against 
(aggressive) recurrent disease and thereby improve outcome. As re-
ported before,30 the outcome of the patients was independent of age at 
the time of diagnosis. It was previously observed in multiple cancer types 
and models that decreased levels of STING lead to poor induction of 
IFN-I.10,12-16,34 To possibly explain the worse survival of patients with ho-
mozygous variants of STING, we assessed the mRNA and protein levels 
of STING. However, we did not observe lower expression of STING1 and 
STING in the patients with homozygous variants as compared with pa-
tients with at least one wild-type allele. Moreover, survival was compara-
ble for high vs low levels of both. After 60 months of follow-up, patients 
with STING1 mRNA expression above median appear to gain a slight sur-
vival advantage. We determined mRNA levels using cervical scrapings 
and lack material to determine potential change in mRNA levels during 
follow-up time that may explain this advantage. Possibly, a higher mRNA 
level at baseline may provide a long-term survival advantage. However, 
based on our data, we cannot draw any conclusions on this.
Despite apparent intact translation, STING variants may be dys-
functional. For example, it was described that the R232H, G230A, 
and R293Q substitutions are located in the cyclic dinucleotide 
(CDN)-binding region of the gene and cause defective response of 
STING.23 A recent study regarding the effect of the homozygous 
HAQ variant of STING in individuals infected with HIV showed that 
this variant contributes to reduced levels of IFN production and 
a reduced immune response.24 In accordance, it is reported that 
this variant is associated with defective functionality of STING 
due to the occurrence of the rs13181561 substitution upstream of 
STING1 in individuals with HAQ/HAQ variants of STING1.19,20 We 
did not look into HPV proteins, nor did we assess the presence of 
the rs13181561 substitution and other substitutions such as the 
synonymous rs744792735 that has been reported previously with 
regard to other cancer types. In addition, the limited availability of 
cDNA did not allow us to study the IFN-I mRNA levels.
As IFN-I signaling ultimately leads to infiltration of CD8 T cells, we 
performed immunohistochemistry for CD8 on available tumor tissue. 
We observed no difference in CD8+ T cell numbers between the patient 
groups with different STING1 variants, indicating intact IFN signaling in 
patients with hetero- and homozygous variants of STING. However, it 
was formerly reported that HPV+ human head and neck squamous cell 
carcinomas present with less clonal expansion of cytotoxic T cells and 
lower levels of antigen-presenting machinery than carcinomas lacking 
HPV.36 As cervical cancers are almost exclusively HPV+, it is possible 
that although patients with homozygous variants of STING have similar 
numbers of CD8+-infiltrated cells compared with patients with at least 
one wild-type allele, these CD8 infiltrates may merely represent irrele-
vant “bystander” CD8 cells that do not effectuate actual antitumor im-
munity. In line, Fu et al showed in mice that activation of dendritic cells 
was associated with STING-dependent phosphorylation of IRF3, and that 
antitumor efficacy upon treatment with a CDN-based vaccine depended 
on STING and CD8+ T cells.37 Moreover, immune checkpoint inhibition 
did not induce tumor regression in the context of STING loss,8 suggesting 
a lack of tumor-reactive CD8+ T cells. Studies are currently ongoing to 
induce STING-mediated immunity, either directly via eg STING agonists18 
or indirectly through radiotherapy or inhibition of the DNA damage repair 
pathway.38 As we speculate that homozygous variants of STING are as-
sociated with impaired antitumor immunity and fail to induce the activa-
tion of tumor-reactive CD8+ T cells, we hypothesize that STING-inducing 
therapy may not be effective in patients with these variants. Therefore, 
we recommend that these studies should include the effect of various 
STING1 variants on (immune)therapeutic response against cervical cancer.
Additionally, treatment regimens for cervical cancer are primar-
ily determined based on FIGO stage. Early-stage cancer is usually 
treated with surgery, whereas for late-stage disease, patients can 
be treated with primary or palliative (chemo)radiation therapy or 
a combination treatment.32 In accordance with their large propor-
tion of early FIGO stages and small tumors, patients with VAR/VAR 
genotypes of STING are mainly treated with surgery. However, we 
demonstrated that these patients have a poor outcome and ob-
served a survival disadvantage even in the group of patients that 
were primarily treated with RCT. Therefore, we speculate the treat-
ment regimen for patients with homozygous variants of STING may 
be ineffective and potentially should be reconsidered.
Finally, although V48V was previously associated with esoph-
ageal squamous cell carcinoma in Chinese individuals,35 here it 
appeared to be more abundant in the European reference cohort 
than in the (Dutch) patient and healthy control cohorts (patient vs 
European reference cohort P = .074). Interestingly, despite repre-
senting a synonymous substitution, V48V was previously reported 
to be in linkage disequilibrium with both HAQ and R232H and the 
rs13181561 substitution, making it a surrogate marker for loss of 
STING function.35 Here, we showed that the V48V indeed corre-
sponded to homozygous variants of STING1 and that it was indi-
vidually prognostic for outcome. As the allelic variants represent 
germline and not somatic substitutions specific for the cervical tis-
sue, it is possible to identify V48V in the DNA of patients, which may 
facilitate genotyping for prognostic purposes.
Altogether, our results suggest that patients with homozygous 
allelic variants of the STING1 gene have worse DSS and recur-
rence-free survival and earlier age of diagnosis than patients with at 
least one wild-type STING1 allele. Homozygous V48V was found to 
be individually prognostic and may be investigated as a novel, surro-
gate prognostic biomarker in cervical cancer.
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